Two retrospective analyses have revealed that the introduction of biosimilars has reduced the costs of the originator biologic, infliximab, but it’s uncertain if these savings are benefiting patients or increasing drug access. The studies, focusing on Medicare Part D participants and private insurance patients, showed a decrease in the annual increase rate of infliximab costs and claims after biosimilars were introduced. Despite the clear cost reductions, concerns remain about whether these savings are reaching patients, especially in terms of copays or changes in access to the medication.
Key Insights
- Cost Reduction by Biosimilars: The introduction of biosimilars has successfully reduced the cost of infliximab, a trend observed in both Medicare and private insurance sectors.
- Uncertainty in Patient Benefit: Despite the cost reductions, it’s unclear if these savings are being passed on to patients in the form of lower copays or improved access to the medication.
- Variable Impact Across States: The impact of biosimilars varies across different states, indicating a need for further investigation into regional trends and policies.
- Potential for Improved Healthcare Economics: The significant cost savings from biosimilars could potentially lead to broader healthcare benefits, but this depends on how these savings are utilized within the healthcare system.
Image Source & Credit: Medscape